Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Ophthalmology. 2015 Mar;122(3):600-9. doi: 10.1016/j.ophtha.2014.09.029. Epub 2014 Nov 13.
To report the long-term outcome of primary transpupillary thermotherapy (TTT) for choroidal melanoma.
Retrospective review of medical records.
We included 391 patients with choroidal melanoma treated between 1995 and 2012 at the Oncology Service, Wills Eye Hospital, Philadelphia.
We delivered TTT with an infrared diode laser.
Local tumor recurrence, Snellen visual acuity after TTT, and distant metastasis.
Of 391 patients, 311 (80%) were treated from 1995 to 2000 and 80 (20%) from 2001 to 2012. Tumors in the 2001 to 2012 group were ultrasonographically thinner (2.2 vs. 2.7 mm), more distant from the optic disc (3.2 vs. 2.5 mm) and foveola (4.0 vs. 2.0 mm), were less often located in the macular area (14% vs. 40%), and had lower rates of acoustic hollowness on B-scan ultrasonography (63% vs. 84%), subretinal fluid (58% vs. 90%), and orange pigment (50% vs. 70%). Kaplan-Meier estimates for tumor recurrence in the 1995 to 2000 group were 29% at 5 years and 42% at 10 years, whereas estimates for tumor recurrence in the 2001-2012 group were 11% at 5 years and 15% at 10 years. Of 108 recurrent tumors 20 were controlled with additional TTT and 62 required plaque radiation (n=60) or proton beam radiation (n=2), with enucleation necessary in 26 patients. Tumor recurrence correlated with the number of high-risk tumor features: 10-year recurrence was 18% in those with 1 or 2 risk factors, 35% in those with 3 to 5 factors, and 55% in those with 6 or 7 factors. On multivariate analysis, features predictive of tumor recurrence were presence of symptoms (P<0.001), shorter distance between the tumor and the optic disc (P=0.026), subretinal fluid (P=0.035), thickness of residual tumor scar (P<0.001), and elevation of residual tumor scar (P<0.001). The only factor predictive of extraocular tumor extension was intraocular tumor recurrence after TTT treated with additional TTT (P=0.007). Presence of orange pigment before TTT (P=0.019), tumor recurrence (P=0.002), and extraocular tumor extension (P=0.017) were predictive of distant metastasis.
This study shows a direct correlation between a larger number of high-risk tumor features and higher rates of tumor recurrence after primary TTT of (small) choroidal melanoma. We advise that, when possible, small choroidal melanomas with multiple risk factors be treated with methods other than TTT.
报告原发性经瞳孔温热疗法(TTT)治疗脉络膜黑色素瘤的长期结果。
病历回顾性研究。
我们纳入了 1995 年至 2012 年期间在费城威尔斯眼医院肿瘤科接受治疗的 391 例脉络膜黑色素瘤患者。
我们使用红外二极管激光进行 TTT。
局部肿瘤复发、TTT 后的 Snellen 视力和远处转移。
391 例患者中,311 例(80%)于 1995 年至 2000 年接受治疗,80 例(20%)于 2001 年至 2012 年接受治疗。2001 年至 2012 年组的肿瘤在超声下更薄(2.2 毫米比 2.7 毫米),距视盘(3.2 毫米比 2.5 毫米)和黄斑(4.0 毫米比 2.0 毫米)更远,更常位于黄斑区(14%比 40%),B 型超声检查时声影空洞(63%比 84%)、视网膜下积液(58%比 90%)和橙色色素(50%比 70%)发生率较低。1995 年至 2000 年组肿瘤复发的 Kaplan-Meier 估计值为 5 年时 29%,10 年时 42%,而 2001-2012 年组肿瘤复发的 Kaplan-Meier 估计值为 5 年时 11%,10 年时 15%。在 108 例复发肿瘤中,20 例经额外 TTT 控制,62 例需行敷贴放疗(n=60)或质子束放疗(n=2),26 例患者需行眼球摘除术。肿瘤复发与高危肿瘤特征的数量有关:有 1 或 2 个危险因素者 10 年复发率为 18%,有 3 至 5 个危险因素者为 35%,有 6 或 7 个危险因素者为 55%。多因素分析显示,肿瘤复发的预测因素为存在症状(P<0.001)、肿瘤与视盘之间的距离较短(P=0.026)、视网膜下积液(P=0.035)、残余肿瘤瘢痕厚度(P<0.001)和残余肿瘤瘢痕隆起(P<0.001)。唯一预测眼内肿瘤延伸的因素是 TTT 后出现眼内肿瘤复发并接受额外 TTT 治疗(P=0.007)。TTT 前存在橙色色素(P=0.019)、肿瘤复发(P=0.002)和眼外肿瘤延伸(P=0.017)是远处转移的预测因素。
本研究表明,原发性 TTT 治疗小(小)脉络膜黑色素瘤后,肿瘤特征数量越多,肿瘤复发率越高。我们建议,如有可能,应采用 TTT 以外的方法治疗具有多种危险因素的小脉络膜黑色素瘤。